The random sample survey of non-fatal home accidental injuries, Cambridge, Mass. in 1952

Thesis (Ed.M.)--Boston Universit

On the Road Again

Billboards, the advertising behemoths that line our highways, did you ever wonder just what happens to them after their month or more appearance on Route 35? I set out to find out the answer to that very question and to find out if the material was suitable for apparel. The answer is: they are taken down and rolled up bundled in a tight dirty roll with duct tape then tossed in a dingy warehouse on the outskirts of an industrial park and after a few months in that state they most likely become part of the local landfill! Discovering this I set out to repurpose a discarded billboard skin into a functional creative garment that would be deemed marketable to the contemporary woman.</p

Morph

‘Morph’ is part of my thesis collection, ‘Insected’, which I began in January of 2014.</p

Winged

‘Winged’ is part of my thesis collection, ‘Insected’, which I began in January of 2014.</p

Elytra

‘Elytra’ is part of my thesis collection, ‘Insected’, which I began in January of 2014.</p

Teaching design research through practice: a pilot study for collaborative exploration

As design educators, we experience tension between devoting the precious little time we have in class to educating our students in ways of making (i.e., skills in sewing and patternmaking) and ways of thinking (i.e. design ideation, creativity, etc.).</p

Highly Sensitized Patients: Miami Transplant Institute Experience

BACKGROUNDTransplantation continues to be challenging in highly sensitized patients. Herein, we compared induction immunosuppression (IS) based on immunologic risk stratification and desensitization with intravenous immunoglobulin (IVIG).METHODSOf the 42 highly sensitized kidney and 3 kidney-pancreas transplant recipients who underwent IVIG for desensitization from 2008-2014, 10 (Control group) received standard induction IS with antithymocyte globulin, basiliximab, and methylprednisolone, and 35 (Rituximab group) received standard IS with rituximab ± IVIG ± plasmapheresis. Immunologic risk stratification was based on donor specific antibodies (DSA), flow crossmatch ratio, and calculated panel reactive antibody. All patients received tacrolimus, mycophenolate, and steroids for maintenance IS. Unacceptable antigen cut-offs for class I and II DSA were 6000 and 9000 mean fluorescence intensity and 2.0 and 4.4 channel shift ratios for T and B cell flow cytometry crossmatch, respectively. All complement dependent cytotoxicity T cell crossmatch negative patients were transplanted.RESULTSCharacteristics between groups, including high risk level, previous transplantation rate, number of human leukocyte antigen mismatches, delayed graft function rate, rejection rate, serum creatinine, and estimated glomerular filtration rate at 1 year (1.48 ± 0.6 and 50 ± 17 versus 1.1 ± 0.4 mg/dl and 66 25 ml/min) were not statistically significant between the Control and the Rituximab groups, respectively. Waiting time for the Control group was 6.4 years versus 4.1 years for the Rituximab group (p = 0.009). The cumulative proportion of patients who remain free of death or allograft failure was significantly higher in the Rituximab (87%) versus the Control group (60%) (p = 0.047).CONCLUSIONSIn highly sensitized patients who received desensitization with IVIG, the addition of Rituximab to our standard IS (and/or IVIG and plasmapheresis as per the immunologic risk stratification model) resulted in higher cumulative patient and graft survival